In summary, sBCMA-Fc V3 with enhanced binding affinity to APRIL and BAFF resulted in better antitumor activity in both APRIL-driven MM and BAFF-driven DLBCL models. This evidence concerns the gene TNFSF13B and diffuse large B-cell lymphoma.